Psychopharmacology, 2013: A Master Class
Ross J. Baldessarini, MD, DSC (Hon), Nassir Ghaemi, MD, MPH, Thomas G. Gutheil, MD, Jeffrey Lieberman, MD, Lawrence E. Lifson, MD, Charles Nemeroff, MD, PHD, Carl Salzman MD, Alan F. Schatzberg, MD, David Sheehan, MD, MBA, Daniel Weinberger, MD, Roger Weiss, MD, John Winkelman, MD, PHD, Kimberly Yonkers, MD
This unique two-day course is designed for the experienced clinician. The conference will focus on emerging developments in the neurobiology and clinical treatment of mental disorders. Course participants will be expected to have had clinical experience, familiarity with the neurobiological and genetic contributions to psychiatric illnesses as well as an understanding of the basic therapeutic mechanisms of psychotropic medications. There will be considerable opportunity for interaction with the presenters.
This conference will focus on the following topics: An updated review of neurobiology and brain function will be presented, taking the attendee through neurotransmission sequence from neurotransmitter and synaptic function synthesis to gene transcription. The interaction between genes and the environment will be emphasized. The current use of antipsychotic drugs and mood stabilizing drugs for the treatment of schizophrenia and bipolar disorder will be presented; new antipsychotic medications will also be discussed along with potential new uses for mood stabilizers. A comprehensive review of the neurobiology and genetic predisposition to depression will be emphasized along with the modern use of antidepressants based on the latest research findings. Treatment of Bipolar Depression will be highlighted. The neurobiological mechanisms of anxiety and anxiety-spectrum disorders as well as their treatment will be reviewed, including obsessive-compulsive disorder, panic disorder, social anxiety disorder, PTSD, and generalized anxiety disorder. The neurobiological mechanisms of stress will also be emphasized. The importance of the evaluation and psychopharmacological treatment of women’s mental health issues will be featured with particular emphasis on PMS, perinatal, and postpartum disorders. The course will also include a review of the role of psychopharmacology in the treatment of personality and sleep disorders. Advances in the neurobiology and treatment of alcohol and substance abuse disorders will be discussed. The latest advances in child, adolescent and geriatric psychopharmacology will be emphasized. A risk management approach to presenting medication will be taught. Throughout the course the establishment and importance of the therapeutic alliance when prescribing all psychotropic medications will be underscored, as will the potential hazards/benefits of polypharmacy drug interactions.
- Apply in practice the latest advances in the neurobiology of psychiatric disorders and psychopharmacologic therapies;
- Discuss current mechanisms of psychotropic drug treatment;
- Explain the mechanisms and treatment of schizophrenia, bipolar, depression, and anxiety disorders;
- Describe psychopharmacologic treatment of women’s mental health issues;
- Discuss the mechanisms and treatment of sleep disorders and substance abuse disorders;
- Know the legal risks of prescribing medication;
- Assess the latest advances in geriatric psychopharmacology.
Beth Israel Deaconess Department of Psychiatry Foundation, Inc./Contact Hours: 12.75
The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Harvard Medical School designates this live activity for a maximum of 12.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the criteria for 1 hour of Risk Management credit(s) in Massachusetts. Risk management credit(s) were determined based on criteria outlined by the Massachusetts Board of Registration in Medicine. Please check with your individual state licensing board requirements before claiming risk management credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses: Beth Israel Deaconess Medical Center Nursing Education is an approved provider of continuing nursing education by the Massachusetts Association of Registered Nurses Credentialing Center’s Commission on Accreditation.
Psychologists: The Continuing Education Program at Beth Israel Deaconess Medical Center, a major teaching hospital of Harvard Medical School is approved by the American Psychological Association to offer continuing education to psychologists. The Continuing Education Program at Beth Israel Deaconess Medical Center, a major teaching hospital of Harvard Medical School is responsible for this program.